Filing Flows

Filing Flows › Companies › Regenerative Medical Technology Group › Cash flow

Regenerative Medical Technology Group cash flow, quarter by quarter

Latest: Q2 2026 · from the cash-flow statements filed with the SEC

Free cash flow$288K in Q2 2026 · −$582K over twelve months

Operating cash flow$332K
Capital spending−$43K
Free cash flow+$288K

Analysis

In Q2 2026, Regenerative Medical Technology Group generated $332K of operating cash flow and spent $43K on capital projects, leaving free cash flow of $288K. That is $887K more than in Q2 2025 (−$598K).

Over the twelve months to Jun 30, 2026, operating cash flow was $269K; the largest uses were capital spending ($851K); besides operations, cash came from net borrowing (+) / repaid (−) ($291K); the cash balance fell by $291K.

Operating cash flow was $332K against net income of −$2.9M. The largest differences: payables +$1.7M, prepaid and other assets −$199K, inventory −$183K.

Free cash flow

Regenerative Medical Technology Group: free cash flow by quarterRegenerative Medical Technology Group: free cash flow by quarter$219KQ3 2024$329KQ4 2024$57KQ1 2025−$598KQ2 2025−$429KQ3 2025−$229KQ4 2025−$213KQ1 2026$288KQ2 2026
Operating cash flow less capital spending.
Regenerative Medical Technology Group: operating cash flow against capital spendingRegenerative Medical Technology Group: operating cash flow against capital spendingOperating cash flowCapital spending$273K$54KQ3 2024$379K$50KQ4 2024$57K$0Q1 2025−$598K$0Q2 2025−$204K$225KQ3 2025$38K$267KQ4 2025$102K$315KQ1 2026$332K$43KQ2 2026
Latest (Q2 2026): Operating cash flow $332K, Capital spending $43K.

Capital allocation, year by year

Regenerative Medical Technology Group: where the cash came from (up) and went (down), by fiscal yearRegenerative Medical Technology Group: where the cash came from (up) and went (down), by fiscal yearOperating cash flowNet borrowingCapital spendingFY2021: Operating cash flow −$9.9MFY2021: Net borrowing $12.4M$12.4MFY2021FY2022: Operating cash flow −$1.1MFY2022: Net borrowing −$21KFY2022: Capital spending −$198KFY2022FY2023: Operating cash flow −$419KFY2023: Net borrowing −$10KFY2023: Capital spending −$386KFY2023FY2024: Operating cash flow $851KFY2024: Capital spending −$215K$851KFY2024FY2025: Operating cash flow −$707KFY2025: Net borrowing $1.1MFY2025: Capital spending −$603K$1.1MFY2025
Over these 5 years operating cash flow totalled −$11.3M; the largest uses were operating cash flow ($12.1M) and capital spending ($1.4M). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$1.3M
Debt$4
Net cash$1.3M

Regenerative Medical Technology Group's operations bring cash in ($269K over twelve months), and it spends more than that on capital projects: a gap of $582K funded from its $1.3M of cash and investments and from borrowing ($4 of debt). That is a choice to invest, not a cash runway running down.

Where the cash came from and went

Regenerative Medical Technology Group: sources (+) and uses (−) of cash, Q2 2026Regenerative Medical Technology Group: sources (+) and uses (−) of cash, Q2 2026Operating cash flow$332KCash drawn (+) / kept (−)−$262KCapital spending−$43KNet borrowing (+) / repaid (−)−$27K
Regenerative Medical Technology Group: sources (+) and uses (−) of cash, TTM to Q2 2026Regenerative Medical Technology Group: sources (+) and uses (−) of cash, TTM to Q2 2026Capital spending−$851KNet borrowing (+) / repaid (−)$291KCash drawn (+) / kept (−)$291KOperating cash flow$269K

From profit to cash

Regenerative Medical Technology Group: net income to operating cash flow, Q2 2026Regenerative Medical Technology Group: net income to operating cash flow, Q2 2026Net income−$2.9MDepreciation & amortization$91KReceivables−$75KInventory−$183KPayables$1.7MPrepaid and other assets−$199KOperating cash flow$332K
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.

Every quarter

QuarterOperating cash flowCapital spendingNet borrowing (+) / repaid (−)Cash drawn (+) / kept (−)Free cash flow
Q2 2026$332K−$43K−$27K−$262K$288K
Q1 2026$102K−$315K$318K−$105K−$213K
Q4 2025$38K−$267K—$229K−$229K
Q3 2025−$204K−$225K—$429K−$429K
Q2 2025−$598K——−$391K−$598K
Q1 2025$57K——−$57K$57K
Q4 2024$379K−$50K—−$329K$329K
Q3 2024$273K−$54K—−$219K$219K

Regenerative Medical Technology Group: income statement and cash flow

Regenerative Medical Technology Group, Q2 2026: revenue $4.0M (+309% year over year), operating margin 14.1%. The chart follows the revenue to costs, profit and cash.

Regenerative Medical Technology Group: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.